SV2017005577A - Metodos para diagnosticar y tratar el cancer - Google Patents

Metodos para diagnosticar y tratar el cancer

Info

Publication number
SV2017005577A
SV2017005577A SV2017005577A SV2017005577A SV2017005577A SV 2017005577 A SV2017005577 A SV 2017005577A SV 2017005577 A SV2017005577 A SV 2017005577A SV 2017005577 A SV2017005577 A SV 2017005577A SV 2017005577 A SV2017005577 A SV 2017005577A
Authority
SV
El Salvador
Prior art keywords
subject
methods
cancer
ntrk3
ntrk2
Prior art date
Application number
SV2017005577A
Other languages
English (en)
Inventor
Brian B Tuch
Josh Bilkener
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of SV2017005577A publication Critical patent/SV2017005577A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE IDENTIFICÓ UNA SERIE DE MUTACIONES PUNTUALES DIFERENTES EN NTRK1, NTRK2 Y NTRK3 EN MUESTRAS DE BIOPSIA DE SUJETOS QUE TENÍAN UNA SERIE DE DIFERENTES CÁNCERES. EN EL PRESENTE DOCUMENTO SE PROPORCIONAN MÉTODOS PARA TRATAR A UN SUJETO QUE TENGA CÁNCER, MÉTODOS PARA SELECCIONAR UN TRATAMIENTO QUE INCLUYA UN CANTIDAD TERAPÉUTICAMENTE EFICAZ DE UN INHIBIDOR DE TRK PARA UN SUJETO, MÉTODOS PARA DETERMINAR LA PROBABILIDAD DE QUE UN SUJETO QUE TIENE UN CÁNCER TENDRÁ UNA RESPUESTA POSITIVA AL TRATAMIENTO CON UN INHIBIDOR DE TRK, MÉTODOS PARA PREDECIR LA EFICACIA DE UN INHIBIDOR DE TRK EN UN SUJETO QUE TIENE UN CÁNCER, MÉTODOS PARA DETERMINAR EL RIESGO DE QUE UN SUJETO DESARROLLE UN CÁNCER Y MÉTODOS PARA AYUDAR EN EL DIAGNÓSTICO DEL CÁNCER QUE ESTÁN BASADOS EN LA IDENTIFICACIÓN DE UN SUJETO QUE TIENE UNA CÉLULA QUE TIENE AL MENOS UNA DE LAS MUTACIONES PUNTUALES EN NTRK1, NTRK2 Y/O NTRK3 O EN LA DETERMINACIÓN DE QUE EL SUJETO TIENE UNA CÉLULA QUE TIENE AL MENOS UNA DE LAS MUTACIONES PUNTUALES EN NTRK1, NTRK2 Y/O NTRK3. TAMBIÉN SE PROPORCIONAN KITS QUE PERMITEN LA DETECCIÓN DE AL MENOS UNA DE LAS MUTACIONES PUNTUALES EN NTRK1, NTRK2 Y/O NTRK3
SV2017005577A 2015-06-01 2017-12-01 Metodos para diagnosticar y tratar el cancer SV2017005577A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562169443P 2015-06-01 2015-06-01

Publications (1)

Publication Number Publication Date
SV2017005577A true SV2017005577A (es) 2018-04-17

Family

ID=56194562

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005577A SV2017005577A (es) 2015-06-01 2017-12-01 Metodos para diagnosticar y tratar el cancer

Country Status (19)

Country Link
US (2) US20180140604A1 (es)
EP (2) EP3722441A1 (es)
JP (1) JP2018526324A (es)
KR (1) KR20180021745A (es)
CN (1) CN107849615A (es)
AU (1) AU2016270803A1 (es)
BR (1) BR112017025773A2 (es)
CA (1) CA2988423A1 (es)
CL (1) CL2017003069A1 (es)
EA (1) EA201792679A1 (es)
HK (1) HK1253093A1 (es)
IL (1) IL256025A (es)
MA (2) MA41667A1 (es)
MX (1) MX2017015461A (es)
PE (1) PE20180329A1 (es)
PH (1) PH12017502200A1 (es)
SV (1) SV2017005577A (es)
TN (1) TN2017000502A1 (es)
WO (1) WO2016196671A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2952692C (en) 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
HUE037716T2 (hu) 2008-10-22 2018-09-28 Array Biopharma Inc Szubsztituált pirazolo[l,5-a]pirimidin vegyületek mint TRK kináz inhibitorok
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
MY191934A (en) 2010-05-20 2022-07-19 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
SI3699181T1 (sl) * 2014-11-16 2023-06-30 Array Biopharma, Inc. Kristalinična oblika(s)-n-(5-((r)-2-(2,5-difluorofenil)- pirolidin-1-il)-pirazolo(1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1 -karboksamid hidrogen sulfata
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
AU2016370846B2 (en) * 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
TN2018000335A1 (en) 2016-04-04 2020-01-16 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2952056T3 (es) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2019018570A1 (en) 2017-07-19 2019-01-24 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
US20190247398A1 (en) * 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109055562B (zh) * 2018-10-29 2022-12-20 深圳市颐康生物科技有限公司 一种生物标志物、预测肾细胞癌的复发和死亡风险的方法
US20220243280A1 (en) * 2019-05-24 2022-08-04 Foundation Medicine, Inc. Ntrk fusion molecules and uses thereof
CN110643672A (zh) * 2019-10-15 2020-01-03 西安交通大学 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途
KR20220008175A (ko) * 2020-07-13 2022-01-20 가톨릭대학교 산학협력단 전립선암 환자의 예후 진단 및 치료 전략 결정용 병리등급 특이적 마커
CN112779147A (zh) * 2020-12-23 2021-05-11 广西大学 一种流化状态对微生物聚集体微观传质及生化反应过程的测量方法及装置

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
JP2004500873A (ja) 2000-06-22 2004-01-15 ジェネンテック・インコーポレーテッド アゴニスト抗−ｔｒｋ−ｃモノクローナル抗体
US20070037150A1 (en) * 2003-02-21 2007-02-15 The Johns Hopkins University Tyrosine kinome
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
WO2006123113A2 (en) 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US8673347B2 (en) 2005-08-25 2014-03-18 Creabilis Therapeutics S.P.A. Polymer conjugates of K-252A and derivatives thereof
MX2009011951A (es) 2007-05-04 2009-12-11 Irm Llc Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
PL2176231T3 (pl) 2007-07-20 2017-04-28 Nerviano Medical Sciences S.R.L. Podstawione pochodne indazolu aktywne jako inhibitory kinazy
CN101909647A (zh) 2007-10-23 2010-12-08 诺瓦提斯公司 TrkB抗体用于治疗呼吸病症的用途
US8642035B2 (en) 2008-01-17 2014-02-04 Irm Llc Anti-TrkB antibodies
ES2532732T3 (es) 2008-07-29 2015-03-31 Nerviano Medical Sciences S.R.L. Uso de un inhibidor de CDK para el tratamiento del glioma
CA2952692C (en) * 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
HUE037716T2 (hu) * 2008-10-22 2018-09-28 Array Biopharma Inc Szubsztituált pirazolo[l,5-a]pirimidin vegyületek mint TRK kináz inhibitorok
US8912194B2 (en) 2008-11-24 2014-12-16 Nerviano Medical Sciences S.R.L. CDK inhibitor for the treatment of mesothelioma
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
MY191934A (en) 2010-05-20 2022-07-19 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
CN105130967B (zh) 2011-05-13 2018-04-17 阵列生物制药公司 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物
AU2012339753A1 (en) 2011-11-14 2014-06-19 Tesaro, Inc. Modulating certain tyrosine kinases
US9242977B2 (en) 2012-04-26 2016-01-26 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
JP2013226108A (ja) * 2012-04-27 2013-11-07 Astellas Pharma Inc 新規ｎｔｒｋ２活性化変異の検出法
ES2771100T3 (es) 2012-05-23 2020-07-06 Nerviano Medical Sciences Srl Proceso para la preparación de n-[5-(3,5-difluoro-bencil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetrahidro-piran-4-ilamino)-benzamida
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
JP2014082984A (ja) * 2012-10-23 2014-05-12 Astellas Pharma Inc 新規ｎｔｒｋ２活性化変異の検出法
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
MX365733B (es) 2012-11-13 2019-06-12 Array Biopharma Inc Compuestos de n-pirrolidinil, n' -pirazolil-urea, tiourea, guanidina y cianoguanidina como inhibidores de trka cinasa.
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
EP3459935B1 (en) 2013-02-19 2020-12-23 ONO Pharmaceutical Co., Ltd. Urea derivative as trk-inhibiting compound
WO2015017533A1 (en) 2013-07-30 2015-02-05 Blueprint Medicines Corporation Ntrk2 fusions
EP4338739A3 (en) 2014-01-24 2024-05-29 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
CR20160583A (es) 2014-05-15 2017-02-23 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea como inhibidor de trka cinasa
ES2732026T3 (es) 2014-08-18 2019-11-20 Ono Pharmaceutical Co Sal de adición de ácido de un compuesto inhibidor de Trk
SI3699181T1 (sl) 2014-11-16 2023-06-30 Array Biopharma, Inc. Kristalinična oblika(s)-n-(5-((r)-2-(2,5-difluorofenil)- pirolidin-1-il)-pirazolo(1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1 -karboksamid hidrogen sulfata

Also Published As

Publication number Publication date
PE20180329A1 (es) 2018-02-13
MA41667A1 (fr) 2018-08-31
CL2017003069A1 (es) 2018-06-01
CN107849615A (zh) 2018-03-27
IL256025A (en) 2018-01-31
AU2016270803A1 (en) 2018-01-04
PH12017502200A1 (en) 2018-06-11
JP2018526324A (ja) 2018-09-13
US20220088021A1 (en) 2022-03-24
KR20180021745A (ko) 2018-03-05
TN2017000502A1 (en) 2019-04-12
EP3303631A1 (en) 2018-04-11
WO2016196671A1 (en) 2016-12-08
MA44936A1 (fr) 2021-09-30
US20180140604A1 (en) 2018-05-24
BR112017025773A2 (pt) 2018-08-14
EP3722441A1 (en) 2020-10-14
EA201792679A1 (ru) 2018-06-29
HK1253093A1 (zh) 2019-06-06
CA2988423A1 (en) 2016-12-08
MX2017015461A (es) 2018-08-15

Similar Documents

Publication Publication Date Title
SV2017005577A (es) Metodos para diagnosticar y tratar el cancer
SV2018005677A (es) Mutaciones puntuales en cancer resistente a trk y metodos relacionados con las mismas
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1123067T1 (el) Μεθοδοι αγωγης ασθενων καρκινων με αναστολεις τρανσφερασης φαρνεσυλιου
EA202091540A1 (ru) Антитела к lilrb2
EA201792642A1 (ru) Способы диагностики для т-клеточной терапии
BR112018075288A2 (pt) métodos para diagnóstico de infecções bacterianas e virais
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
AR102345A1 (es) Uso de paneles del gen mutante del fgfr en la identificación de pacientes de cáncer que serán sensibles al tratamiento con un inhibidor del fgfr
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
MX2022014633A (es) Metodos para detectar norovirus.
BR112016029521A2 (pt) ?kit, dispositivo e método para a detecção de câncer de estômago?
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
BR112016006312A2 (pt) método e kit para determinar a presença ou ausência de staphylococcus aureus resistente à meticilina em uma amostra biológica
GB2540702A (en) Nucleic acid processing of a nucleic acid fragment with a triazole linkage
MX2021009528A (es) Prueba de diagnostico basada en fragmento de rgma.
EA201990730A1 (ru) Рнк-биомаркеры для наследственного ангионевротического отека
CY1122474T1 (el) Μεθοδος διαγνωσης νευραλγιας του τριδυμου
SV2017005459A (es) Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr
BR112017017878A2 (pt) método, suporte e kit de coleta de ácido(s) nucleico(s)
WO2016004375A3 (en) Methods and materials for treating pain and depression
BR112016020043A2 (pt) composições e métodos para a identificação de malignidades de linfócitos b responsivas à terapia de depleção de linfócitos b
MX2019002932A (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto.
JOP20170191A1 (ar) طرق تشخيص و علاج السرطان